ISSN: 2381-8727



当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得


Study of Plasma End statin Level in Patients with Myeloid Leukaemia

Dr. Haggag R

Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy characterized by accumulation of immature malignant myeloid cells in the bone marrow and blood due to their clonal proliferation without substantial maturation [1]. Angiogenesis is the formation of new vessels from an existing network of vasculature [2]. Irrespective of cellular origin, induction of angiogenesis requires a shift/switch towards activation/upregulation of inducers of angiogenesis over suppression of angiogenic inhibitors (hereafter AI). Some key angiogenic activators include vascular endothelial growth factor A hereafter VEGF (VEGF-A) [3], Matrix Metalloproteinases (MMPs), Placenta Growth Factor (PlGF), Fibroblast Growth Factor (FGF) and Hepatocyte Growth Factor (HGF) [4]. Endogenous inhibitors of angiogenesis include Thrombospondins (THSBs) endostatin, angiostatin and cytokines such as interleukin- 12 [5]. The crucial role of angiogenesis in the growth, persistence, and metastases of solid tumors has been indicated in many studies [6,7]. There is mounting evidence that angiogenesis is also significant in leukemia [8].